Lung Cancer

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Stock Price & Recent Performance Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours trading (October 14) to roughly $0.36 on the cancer data announcement benzinga.com benzinga.com. That rally brought the stock briefly near its 30-day resistance around $0.26 ainvest.com. Before this spike, GNPX had been trading around $0.20. Over the last five trading days the stock was up about 25.6%, although year‐to‐date it was still down roughly 70% benzinga.com. For context, GNPX’s 52-week high is ~$4.09 (achieved in 2024) and its

15 October 2025

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

In April 2025, Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation. The device pairs an immunohistochemistry stain for TROP2 with a digital pathology AI algorithm that runs in Roche’s Navify system to analyze NSCLC biopsy slides. The AI calculates a Normalized Membrane Ratio (NMR), the ratio of surface TROP2 to internal TROP2, to classify tumors as TROP2-positive or -negative. The Ventana TROP2 RxDx is a full diagnostic system, including Roche’s slide scanners, the Navify image management software, the Ventana TROP2 IHC kit, and the AI algorithm. A positive NMR score thresholds

17 July 2025

AI in Healthcare · FDA Approvals · Medical Diagnostics · NYSE:AZN · NYSE:RHHBY · Oncology · Technological Innovation